Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: Efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïeve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. ESMO 2017 Congress; abstract LBA5.
Ontdekking target tripelnegatieve borstkanker opent deur voor nieuwe immuuntherapie
sep 2024 | Borstkanker, Immuuntherapie